Regular Dose of Aspirin To Reduce Risk of Inherited Bowel Cancer

A regular dose of aspirin to reduce the risk of inherited bowel cancer lasts at least 10 years after stopping treatment, research has revealed. The international trial - known as CAPP2 – involved patients with Lynch syndrome from around the world and revealed that two aspirins a day, for an average of two and a half years, reduced the rate of bowel cancer by half. The study, led by experts at the Universities of Newcastle and Leeds, published in The Lancet today, is a planned double-blind 10 year follow–up, supplemented in more than half of recruits with comprehensive national cancer registry data for up to 20 years. Supports national guidance The findings of the study further strengthens the National Institute for Health and Care Excellence (NICE) recommendation on taking daily aspirin for those at high risk and supports wider use of aspirin to prevent cancer. https://www.technologynetworks.com/drug-discovery/news/regular-dose-of-aspirin-to-reduce-risk-of-inherited-bowel-cancer-336022?utm_campaign=NEWSLETTER_TN_Breaking%20Science%20News&utm_medium=email&_hsmi=89412893&_hsenc=p2ANqtz-_zKODGi_A20vu_jiD3nIeikKhCzGUxcr7yPLSSmdWkjCDYILtg3TZudJ65nBr_j-FxkNa-sLtAX1OEg3ldFQwgnKtG4w&utm_content=89412893&utm_source=hs_email